Nasal Polyposis Epidemiology Forecast 2025-2034

Nasal polyposis is characterized by the formation of noncancerous growths form in the nose or sinuses. Nasal polyps grow in groups and are usually shaped like teardrops. The condition can affect approximately 40% of the general population, with the overall risk increasing with age. Nasal polyps are nearly twice as common in individuals assigned male at birth.

Nasal Polyposis Epidemiology Forecast Report Coverage

The “Nasal Polyposis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of nasal polyposis. It projects the future incidence and prevalence rates of nasal polyposis across various populations. The study covers age, gender, and type as major determinants of the nasal polyposis-affected population. The report highlights patterns in the prevalence of nasal polyposis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of nasal polyposis in the 8 major markets.

Regions Covered

• The United States
• The United Kingdom
• France
• Italy
• Spain
• Germany
• Japan
• India

Nasal Polyposis Disease Overview

In nasal polyposis, soft and painless noncancerous growths are formed in the lining of the nose or sinuses. The condition commonly occurs in individuals with allergies, repeat infections, or asthma. Small nasal polyps are shaped like teardrops but the larger ones are similar to peeled grapes that are yellow, pink, or gray in color. As the small polyps start to grow in the nose, symptoms such as nasal congestion, headaches, rhinorrhea, sinus pressure, and snoring are often observed.

Nasal Polyposis: Treatment Overview

Treatment for nasal polyposis depends on the severity of the condition. Medications can help manage symptoms. Steroid nasal sprays can reduce symptoms and may also shrink polyps. Oral steroids such as prednisone and biologics like dupilumab injections are also prescribed to the patients. Surgical removal of nasal polyps is another alternative but there is a likelihood of recurrence.

Epidemiology

The nasal polyposis epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for nasal polyposis by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for nasal polyposis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• As per the American Academy of Allergy, Asthma & Immunology (AAAAI), approximately 20% of chronic rhinosinusitis patients are affected by nasal polyps. Further, around 26 to 56% of patients having chronic rhinosinusitis with nasal polyps suffer from asthma.
• In the United States, the overall incidence of pediatric nasal polyps is reported to be 0.1%. However, in children with cystic fibrosis, the incidence is estimated to be 6 to 48%.
• Studies show that benign multiple nasal polyposis is more common in patients aged over 40 years and is rare in children aged less than 10 years old. Further, the male-to-female ratio in adults is reported to be 2-4:1.
• About 10 to 30% of chronic rhinosinusitis patients have nasal polyps, with the average age of diagnosis estimated to be between 40 to 60 years, according to Raciborski, Filip et al. (2021).

Country-wise Nasal Polyposis Epidemiology

The nasal polyposis epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of nasal polyposis varies between countries owing to the differences in factors such as genetics, environmental exposures, lifestyle patterns, healthcare access, and diagnostic criteria. The prevalence of underlying allergic and inflammatory conditions, like asthma, chronic rhinosinusitis, and aspirin-exacerbated respiratory disease, also influence the epidemiological data of nasal polyposis. In the United States, the incidence of nasal polyps is estimated to be 1 to 4%, with a range of 0.2 to 28%.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of nasal polyposis based on several factors.
• Nasal Polyposis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of nasal polyposis are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of nasal polyposis epidemiology in the 8 major markets?
• What will be the total number of patients with nasal polyposis across the 8 major markets during the forecast period?
• What was the country-wise prevalence of nasal polyposis in the 8 major markets in the historical period?
• Which country will have the highest number of nasal polyposis patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of nasal polyposis during the forecast period of 2025-2034?
• What are the currently available treatments for nasal polyposis?
• What are the disease risks, signs, symptoms, and unmet needs of nasal polyposis?

This product will be delivered within 3-5 business days.